Premium
Potentiation by estramustine of the cytotoxic effect of vinblastine and doxorubicin in prostatic tumor cells
Author(s) -
Batra Satish,
Karlsson Richard,
Witt Lisbeth
Publication year - 1996
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19961127)68:5<644::aid-ijc15>3.0.co;2-1
Subject(s) - estramustine , vinblastine , doxorubicin , verapamil , cytotoxicity , cytotoxic t cell , docetaxel , pharmacology , prostate , medicine , cancer research , endocrinology , chemistry , cancer , in vitro , chemotherapy , biochemistry , calcium , prostate disease
The effects of combining estramustine (EM) with vinblastine (VLB) or doxorubicin (DOX) on cellular uptake, cellular retention and cell survival were investigated in Dunning hormoneinsensitive rat prostate AT‐I tumor cells and DU‐145 human prostatic tumor cells. Accumulation of VLB and DOX by AT‐1 cells was less than one‐half of that in DU‐145 cells. Inclusion of EM or estromustine considerably increased uptake of both VLB and DOX in AT‐1 cells but not in DU‐145 cells. Verapamil and tamoxifen also potentiated VLB uptake in AT‐1 cells. A combination of VLB and EM resulted in a considerable synergistic effect on both cytotoxicity and cellular retention of VLB. The presence of P‐glycoprotein (Pgp) in AT‐1 cells could be demonstrated by both Western blots and immunocytochemical detection. Photoaffinity labeling of Pgp by [ 3 H]‐azidopine was clearly inhibited by VLB verapamil and EM. Our data strongly support the argument for a combination of EM with not only VLB but also DOX to improve the therapeutic index in patients with prostate cancer. © 1996 Wiley‐Liss, Inc.